Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, ...

What Is Changing In The Legend Biotech Story Right Now Legend Biotech’s latest model tweaks reflect refinement rather than a reset, with fair value shifting slightly to US$72.41 from US$72.24 and the ...

NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today ...

The partnership brings together Pfizer’s scientific data and therapeutic expertise with Boltz’s open-source AI foundation ...

The Singapore-based AI clinical trial engine powering Asia’s—especially China’s—rapid rise in the biotech industry. Deep ...

Biopharma enters 2026 amid continuing scientific progress and accelerating deal activity, yet its business model is under pressure across every facet of the value chain. Investors are taking note: ...

Noetik CEO and co-founder Ron Alfa, M.D., Ph.D., said the licensing of human foundation models is “a new paradigm in biotech.” With the GSK deal validating the paradigm, in Alfa’s view, Noetik ...

In 2025, made or projected biopharma workforce cuts affected about 42,700 employees, according to BioSpace tallies. BioSpace ...

Sulfolobus islandicus, an archaeal model organism, offers unique advantages for metabolic engineering and synthetic biology ...

Nizwa: A landmark research project on the development of a 3D-bioprinted wound dressing in the health sector has secured ...

G&A Expense -- $1.9 million, down from $2.3 million mainly due to lower compensation and recruitment spending. Cash on ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.